The aging hypertensive heart: A brief update

Nature Clinical Practice Cardiovascular Medicine

Volumn 5, Issue 2, 2008, Pages 104-110

  Susic, Dinko ^a   Frohlich, Edward D ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; RENIN INHIBITOR; SODIUM; THIAZIDE DIURETIC AGENT;

AGING; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CARDIOVASCULAR FUNCTION; COMORBIDITY; CORONARY ARTERY BLOOD FLOW; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DRUG DOSE COMPARISON; ENDOTHELIAL DYSFUNCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

AGE FACTORS; AGING; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COLLAGEN; CORONARY CIRCULATION; DIET, SODIUM-RESTRICTED; ENDOTHELIUM, VASCULAR; FIBROSIS; HEART FAILURE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 38649089492     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1091     Document Type: Review

References (59)

1. Chobanian AV et al.; National High Blood Pressure Education Program Coordinating Committee (2003) The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 289. 2560-2571
2. Lakatta EG and Levy D (2003) Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises. Part II: The aging heart in health: Links to heart disease. Circulation 107: 346-354
3. Assayag P et al. (1997) Senescent heart compared with pressure overload-induced hypertrophy. Hypertension 29: 15-21
4. Olivetti G et al. (1991) Cardiomyopathy of the aging human heart: myocyte loss and reactive cellular hypertrophy. Circ Res 68: 1560-1568
5. Kitzman DW (2000) Heart failure with normal systolic function. Clin Geriat Med 16: 489-512
6. Blacher J and Safar ME (2006) Large artery stiffness and cardiovascular risk: Introduction to risk assessment and new strategies. In Handbook of Hypertension. Volume 23: Arterial Stiffness in Hypertension, 241-256 (Eds Safar ME and O'Rourke MF) Amsterdam: Elsevier
7. Mitchel GF (2004) Arterial stiffness and wave reflection in hypertension: Pathophysiologic and therapeutic implication. Curr Hypertens Rep 6: 436-461
8. Mitchell GF et al. (2004) Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: The Framingham Heart Study. Hypertension 43: 1239-1245
9. Burt VL et al. (1995) Prevalence of hypertension in the US adult population: Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 25: 305-313
10. Kaas DA (2005) Ventricular arterial stiffening: Integrating the pathophysiology. Hypertension 46: 185-193
11. Torella D et al. (2004) Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 over-expression. Circ Res 94: 514-524
12. Lakatta EG (2003) Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises. Part III: Cellular and molecular clues to heart and arterial aging. Circulatton 107: 490-497
13. Burlew BS and Weber KT (2000) Connective tissue and the heart. Functional significance and regulatory mechanisms. Cardiol Clin 18: 435-442
14. Frohlich ED (1990) Left ventricular hypertrophy: An independent factor of risk. Cardiovasc Clin 20: 85-94
15. Levy D et al. (1987) Risk of ventricular arrythmias in left ventricular hypertrophy: The Framingham Heart Study. Am J Cardiol 60: 560-565
16. Kozakova M et al. (2000) Coronary vasodilator capacity and epicardial vessel remodelling in physiological and hypertensive hypertrophy. Hypertension 36: 343-349
17. Frohlich ED (2001) Fibrosis and ischemia: The real risks in hypertensive heart disease. Am J Hypertens 14: 194S-199S
18. Weber KT (1989) Cardiac interstitium in health and disease: The fibrillar collagen network. J Am Coll Cardiol 13: 1637-1652
19. Jugdutt BI (2003) Remodeling of the myocardium and potential targets in the collagen degradatioh and synthesis pathways. Curr Drug Targets Cardiovasc Haematol Disord 3: 1-30
20. Spinale F (2002) Matrix metalloproteinasees: Regulation and dysregulation in the failing heart. Circ Res 90: 520-530
21. Swynghedauw B (1999) Molecular mechanisms of myocardial remodeling. Physiol Rev 79: 215-262
22. Robert V et al. (1997) Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Lab Invest 76: 729-738
23. Shivakumar K et al. (2003) Differential response of cardiac fibroblasts from young adult and senescent rats to ANG II. Am J Physiol Heart Circ Physiol 284: H1454-H1459
24. Diez-Araya G et al. (2003) IGF-1 modulation of rat cardiac fibroblast behavior and gene expression is age dependent. Cell Commun Adhes 10: 155-165
25. Lindsey ML et al. (2005) Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc Res 60: 410-419
26. Zile MR and Brutsaert DL (2002) New concepts in diastolic dysfunction and heart failure. Part I: Diagnosis, prognosis, and measurements of diastolic function. Circulation 105: 1387-1393
27. Rich MW (2006) Heart failure in older adults. Med Clin North Am 90: 863-885
28. Katz AM and Zile MR (2006) New molecular mechanism in diastolic heart failure. Circulation 113: 1922-1925
29. Kitzman DW et al.; Cardiovascular Health Study Research Group (2001) Importance of heart failure with preserved systolic function in patients ≥65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol 87: 413-419
30. Susic D et al. (1998) Coronary hemodynamics in aging spontaneously hypertensive and normotensive Wistar-Kyoto rats. J Hypertens 16 231-237
31. Csiszar A et al. (2002) Aging induced phenotypic changes and oxidative stress impair coronary arteriolar function. Circ Res 90, 1159-1166
32. Tomanek RJ (1990) Reaponse of the coronary vasculature to myocardial hypertrophy. J Am Coll Cardiol 15: 528-533
33. Schiffrin EL (2001) Small artery remodeling in hypertension: Can it be corrected? Am J Med Sci 322: 7-11
34. Folkow B (1995) Hypertensive structural changes in systemic precapillary resistance vessels: How important are they for in vivo hemodynamics? J Hypertens 13 1546-1559
35. Zile MR and Brutsaert DL (2002) New concepts in diastolic dysfunction and diastolic heart failure. Part II: Causal mechanisms and treatment. Circulation 105: 1503-1508
36. van Heerebeek L et al. (2006) Myocardial strudture and function differ in systolic and diastolic heart failure. Circulation 113 1966-1973
37. De Keulanear GW and Brutsaert DL (2007) Systolic and diastolic heart failure: Different phenotypes of the same-disease? Eur J Heart Fall 9: 136-143
38. Stokes GS (2006) Treatment of isolated systolic hypertension. Curr Hypertens Rep 8: 377-383
39. Pinto E (2007) Blood pressure and ageing. Postgrad Med J 83: 109-114
40. Kumar A et al. (2006) Diastolic heart failure in the elderly and the potential role of aldosterone antagonists. Drugs Aging 23 299-308
41. Frohlich ED and Varagic J (2004) The role of sodium in hypertension is more complex than simply elevating arterial pressure. Nat Clin Pract Cardiovasc Med 1: 24-30
42. Gates PE et al. (2004) Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. Hypertension 44: 35-41
43. Bagrov AY and Lakatta EG (2004) The dietary sodium-blood pressure plot "stiffens". Hypertension 44: 22-24
44. Elkareh J et al. (2007) Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension 49: 215-224
45. Taddei S et al. (2006) Endothelium, aging, and hypertension. Curr Hypertens Rep 8: 84-89
46. Barton M (2005) Ageing as a determinant of renal and vascular disease: role of endothelial factors. Nephrol Dial Transplant 20: 486-490
47. Kansui Y et al. (2002) Angiotensin II receptor antagonist improves age-related endothelial dysfunction. J Hypertens 20: 439-446
48. Goto K et al. (2000) Angiotensin-converting enzyme inhibitor prevents age-related endothelial dysfunction. Hypertension 36 581-587
49. Wu G and Meininger CJ (2000) Arginine nutrition and cardiovascular-function. J Nutr 130: 2626-2629
50. Susic D et al. (1999) Prolonged L-arginine on cardiovascular mass and myocardial hemodynamics and collagen in aged spontaneously hypertensive rats and normal rats. Hypertension 33: 451-455
51. Susic D et al. (2001) Isolated systolic hypertension in elderly WKY, is reversed with L-arginine and ACE inhibition. Hypertension 38: 1422-1426
52. Lee AT and Cerami A (1992) Role of glycation in aging. Ann NY Acad Sci 663: 63-70
53. Susic D et al. (2004) Crosilink breakers: A new approach to cardiovascular therapy. Curr Opin Cardiol 19: 336-340
54. Susic D et al. (2004) Cardiovascular and renal effects of a collagen cross-link breaker (ALT-711) in adult and aged spontaneously hypertensive rats. Am J Hypertens 17: 328-333
55. Asif M et al. (2000) An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci USA 97: 2809-2813
56. Vaitkevicius PL et al. (2001) A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci USA 98: 1171-1175
57. Kass DA et al. (2001) Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104: 1464-1470
58. Bakris GL et al. (2004) Advanced glycation end-product cross-link breakers: A novel approach to cardiovascular pathologies related to the aging process. Am J Hypertens 17: 23S-30S
59. Little WC et al. (2005) The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fall 11 191-195